NCT02222610 (RRR) is a Phase 2 clinical trial of 0.5 mg ranibizumab in Radiation Retinopathy, sponsored by Greater Houston Retina Research.

Who is sponsoring NCT02222610?

NCT02222610 is sponsored by Greater Houston Retina Research.

What drugs are being tested in NCT02222610?

Interventions in NCT02222610: 0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP).

What condition does NCT02222610 study?

NCT02222610 studies Radiation Retinopathy.

Is NCT02222610 still recruiting?

NCT02222610 is currently completed. Last updated 24 March 2021.

Are results published for NCT02222610?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-03-24 · How we verify

NCT02222610: RRR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).

Completed Phase 2 Results posted Last updated 24 March 2021

What this trial tests

Phase 2 trial testing 0.5 mg ranibizumab in Radiation Retinopathy in 40 participants. Completed in 1 March 2019.

Timeline

23 September 2014

Primary endpoint
1 March 2019

1 March 2019

Quick facts

Lead sponsor	Greater Houston Retina Research
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	23 September 2014
Primary completion	1 March 2019
Estimated completion	1 March 2019
Sites	4 locations across United States

Drugs / interventions tested

0.5 mg ranibizumab — full drug profile →
Targeted Retinal Photocoagulation (TRP)

Conditions studied

Radiation Retinopathy — all drugs for Radiation Retinopathy →

Sponsor

Greater Houston Retina Research — full company profile →

Who can join

18 and older, any sex, with Radiation Retinopathy. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity at 104 Weeks From Day 0.
Time frame: 104 weeks
Early Treatment Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) utilizes the ETDRS visual acuity chart to measure vision in clinical trials. Standard unit of measure is the number of letters subjects are able to read on the chart.

Sponsor's own description

The purpose of this study is to assess the tolerability and efficacy of ranibizumab treatment administered in subjects with radiation retinopathy

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review.
Toro MD, Gozzo L, Tracia L, Cicciù M, et al · · 2021 · cited 26× · PMID 34680428 · DOI 10.3390/biomedicines9101311
Two-year results for ranibizumab for radiation retinopathy (RRR): a randomized, prospective trial.
Yu HJ, Fuller D, Anand R, Fuller T, et al · · 2022 · cited 4× · PMID 34463842 · DOI 10.1007/s00417-021-05281-2
Current Therapies and Potential Strategies for Uveal Melanoma.
Scoles S, Ganesh S, Yamada KH. · · 2025 · cited 2× · PMID 41737289 · DOI 10.3390/ddc4020014

Verify or expand the search:

Other trials of 0.5 mg ranibizumab

Trials testing the same drug.

NCT04757610 — OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) · Phase 3 · terminated

Other recruiting trials for Radiation Retinopathy

Currently open trials in the same condition.

NCT05844982 — Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Preventio · Phase 3 · recruiting

Other Greater Houston Retina Research trials

Trials by the same sponsor.

NCT05681884 — Safety and Efficacy of Faricimab in Patients With NPDR · Phase 2 · completed
NCT05333055 — Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema · terminated
NCT04708145 — Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subje · Phase 4 · completed
NCT03531294 — Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement · Phase 2 · completed
NCT02299336 — Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02222610 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Greater Houston Retina Research
Last refreshed: 24 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02222610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing